Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes-focus on pancreatitis and pancreas cancer
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes-focus on pancreatitis and pancreas cancer. / Chalmer, Thor; Almdal, Thomas P.; Vilsboll, Tina; Knop, Filip K.
I: Expert Opinion on Drug Safety, Bind 14, Nr. 1, 2015, s. 171-180.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes-focus on pancreatitis and pancreas cancer
AU - Chalmer, Thor
AU - Almdal, Thomas P.
AU - Vilsboll, Tina
AU - Knop, Filip K.
N1 - Publisher Copyright: © 2015 Informa UK, Ltd.
PY - 2015
Y1 - 2015
N2 - Introduction: The glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, is a widely used drug for the treatment of type 2 diabetes. Liraglutide is one of several incretin-based agents that have been suggested to be associated with pancreatitis and pancreas cancer. The suspicion accelerated after publication of an autopsy study claiming increased incidences of several pathological changes in pancreata from patients with diabetes treated with incretin-based drugs.Areas covered: The aim of the present review is to give an overview of the pharmacology of liraglutide and provide a review of adverse reactions associated with liraglutide with a focus on the risk of pancreatitis and pancreas cancer.Expert opinion: When comprehensively reviewing the available literature, no clear and significant associations between liraglutide and pancreatitis and/or pancreas cancer seem evident. However, a recently published analysis suggests a trend toward a slightly elevated risk of pancreatitis with GLP-1 receptor agonists (including liraglutide), which may become statistical significant as more data become available. Well-established side effects are of gastrointestinal origin, typical mild-to-moderate and of transient character. The risk of hypoglycemia associated with liraglutide treatment is low.
AB - Introduction: The glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, is a widely used drug for the treatment of type 2 diabetes. Liraglutide is one of several incretin-based agents that have been suggested to be associated with pancreatitis and pancreas cancer. The suspicion accelerated after publication of an autopsy study claiming increased incidences of several pathological changes in pancreata from patients with diabetes treated with incretin-based drugs.Areas covered: The aim of the present review is to give an overview of the pharmacology of liraglutide and provide a review of adverse reactions associated with liraglutide with a focus on the risk of pancreatitis and pancreas cancer.Expert opinion: When comprehensively reviewing the available literature, no clear and significant associations between liraglutide and pancreatitis and/or pancreas cancer seem evident. However, a recently published analysis suggests a trend toward a slightly elevated risk of pancreatitis with GLP-1 receptor agonists (including liraglutide), which may become statistical significant as more data become available. Well-established side effects are of gastrointestinal origin, typical mild-to-moderate and of transient character. The risk of hypoglycemia associated with liraglutide treatment is low.
KW - Adverse reactions
KW - Cancer
KW - Glucagon-like peptide-1
KW - Liraglutide
KW - Pancreas
KW - Pancreatitis
KW - Type 2 diabetes
U2 - 10.1517/14740338.2015.975205
DO - 10.1517/14740338.2015.975205
M3 - Review
C2 - 25363438
AN - SCOPUS:84918526403
VL - 14
SP - 171
EP - 180
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
SN - 1474-0338
IS - 1
ER -
ID: 305734859